PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Neurosci. Author manuscript; available in PMC May 26, 2009.
Published in final edited form as:
PMCID: PMC2610528
NIHMSID: NIHMS81741
Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo
Emmanuel Planel,1 Pavan Krishnamurthy,1 Tomohiro Miyasaka,2 Li Liu,1 Mathieu Herman,1 Asok Kumar,3 Alexis Bretteville,1 Helen Y. Figueroa,1 Wai Haung Yu,1 Robert A. Whittington,4 Peter Davies,5 Akihiko Takashima,6 Ralph A. Nixon,3 and Karen E. Duff1*
1Columbia University Medical Center, Taub Institute for Alzheimer’s Disease Research, Department of Pathology, New York, New York, United States of America
2Doshisha University, Faculty of Life and Medical Sciences, Department of Medical Life Systems, Kyoto, Japan
3Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, United States of America
4Columbia University, Department of Anesthesiology, New York, New York, United States of America
5Albert Einstein College of Medicine, Department of Pathology, Bronx, New York, United States of America
6The Institute of Physical and Chemical Research (RIKEN), Brain Science Institute, Laboratory for Alzheimer’s Disease, Wako-shi, Saitama, Japan
*Correspondence should be addressed to Dr Karen E. Duff, Columbia University Medical Center, Taub Institute for Alzheimer’s Disease Research, Department of Pathology, P&S #12-440, 630 West 168th Street, New York, NY 10032, U.S.A. Tel.: +1 212-305-8973; Fax: +1 212-342-0119 E-mail: ked2115/at/columbia.edu
In Alzheimer’s disease, tau is hyperphosphorylated, which is thought to detach it from microtubules (MTs), induce MT destabilization, and promote aggregation. Using a previously described in vivo model, we investigated whether hyperphosphorylation impacts tau function in wild-type and transgenic mice. We found that following anesthesia-induced hypothermia, MT-free tau was hyperphosphorylated, which impaired its ability to bind MTs and promote MT assembly. MT-bound tau was more resistant to hyperphosphorylation compared to free tau and tau did not dissociate from MTs in wild-type mice. However, 3-repeat tau detached from MT in the transgenic mice. Surprisingly, dissociation of tau from MTs did not lead to overt depolymerization of tubulin, and there was no collapse, or disturbance of axonal MT networks. These results indicate that, in vivo, a sub-population of tau bound to MTs does not easily dissociate under conditions that extensively phosphorylate tau. Tau remaining on the MTs under these conditions is sufficient to maintain MT network integrity.
Keywords: tau phosphorylation, microtubules, Alzheimer’s disease, anesthesia, hypothermia, tubulin
Tau is a microtubule-associated protein that is abundant in the central nervous system (CNS) and expressed mainly in axons. In the human brain, tau is encoded by a single gene of 16 exons, generating 6 isoforms of 352 to 441 amino acids. Exons 9 to 12 encode the microtubule (MT) binding repeats, and alternate splicing of exon 10 generates tau with either three (3R) or four (4R) repeats. These repeat regions bind to MTs, and promote MT stabilization and polymerization. These functions are negatively regulated by phosphorylation at multiple sites in, and around, the MT binding domain (Buee et al., 2000; Avila et al., 2004).
In Alzheimer’s disease (AD) and other tauopathies, hyperphosphorylated tau protein aggregates and forms paired helical filaments (PHF) that are the main component of intraneuronal neurofibrillary tangles (NFT) primarily found in the somato-dendritic compartment of affected neurons. The appearance of aggregated tau correlates with a loss of MTs and a breakdown of axonal flow (Terry, 1996; Pollak et al., 2003). Thus, the hyperphosphorylation of tau by the deregulation of kinases and/or phosphatases has been proposed to dissociate tau from MTs, thereby destabilizing the MTs and disrupting MT-dependent axonal transport (Trojanowski and Lee, 1994; Mandelkow et al., 2003; Feinstein and Wilson, 2005; Mi and Johnson, 2006). In vitro studies have demonstrated that hyperphosphorylation of tau can indeed induce MT disruption (Ebneth et al., 1999), as well as tau aggregation (Alonso et al., 2001; Sato et al., 2002). However, there is a lack of evidence from in vivo studies to support the assumption that tau hyperphosphorylation detaches tau from microtubules and results in MT breakdown.
To examine MT and tau dynamics in response to phosphorylation, we induced tau hyperphosphorylation in mice by exposing the animals to anesthesia. We have shown previously that anesthesia-induced hypothermia promotes extensive tau hyperphosphorylation at multiple epitopes by directly inhibiting ser/thr protein phosphatase 2A (Planel et al., 2007b). This model system replicates what is seen in the AD brain as decreased PP2A expression (Vogelsberg-Ragaglia et al., 2001; Sontag et al., 2004), and upregulation of its inhibitors (Tanimukai et al., 2005), result in overall inhibition of its activity (Gong et al., 1993; Gong et al., 1995). PP2A inhibition has been proposed to be an important factor in the evolution of the pathology of AD (Tian and Wang, 2002).
Our results show that hyperphosphorylation impaired tau’s ability to bind and polymerize MTs, but did not detach it from MTs in normal mice. Hyperphosphorylation of tau in transgenic mice expressing all six isoforms of human tau (hTau mice) led to specific dissociation of 3R from the MTs in old mice. Neither normal nor hTau mice however, displayed a breakdown of MTs. These results demonstrate that 4R tau is tightly bound to MTs and does not readily dissociate, whereas 3R is more sensitive to the effects of phosphorylation, thus resulting in dissociation from the MTs. However, this dissociation does not lead to catastrophic collapse of the MT network.
Animals
Adult C57BL/6J (Jackson Laboratory, Bar Harbour, ME) or hTau mice (Andorfer et al., 2003) of either sex were used at 3-4 month-old (young mice) or 18-20 month-old (old mice). Animals were used according to National Institute of Health / Institutional Animal Care and Use Committee Guidelines.
Anesthesia
Anesthesia was induced by intra-peritoneal injections of pentobarbital (Nembutal, 100 mg/kg; Abbot Laboratories, North Chicago, IL), and the animals were kept at room temperature for 1 or 4 h before sacrifice. Mice were killed by cervical dislocation, brains were removed and the tissue was dissected quickly. The whole process took less than 1 min. The control injections were performed with vehicle (50% water, 40% propylene glycol, 10% ethanol). Mouse body temperature was monitored with a rectal probe (Thermalert TH-5, Physitemp, Clifton, NJ).
Microtubule Assays
We performed 3 microtubule assays. The first preserves the association of tau and MTs found in the brain, and is thus called here Endogenous Microtubule Binding Assay because it examines the association of endogenous tau to endogenous MTs. The second assay dissociates endogenous tau from endogenous microtubules and examine the association of tau with preformed bovine microtubules; it is called here Exogenous Microtubule Binding Assay. The third one is a MT Assembly Assay performed with bovine tubulin and endogenous tau.
Endogenous Microtubule Binding Assays
To determine whether tau hyperphosphorylation could detach tau from microtubules, a MT binding assay was performed using a modification of previously reported procedures (Bramblett et al., 1993; Merrick et al., 1996; Vogelsberg-Ragaglia et al., 2000). Following dissection, fresh cortices were immediately homogenized in 5x weight/volume of pre-warmed (37°C) modified reassembly (RA) buffer (0.1 MES, pH 6.5; 0.5 mM MgSO4; 2 mM GTP; 1 mM EGTA; 2 mM DTT; 20 μM taxol; 0.1% Triton X-100; 1 mM PMSF; 1 mM Na3VO4; 1 mM NaF; 10 μl/ml Sigma Protease Inhibitor Cocktail P8340), in a warm (37°C) glass-teflon homogenizer (Weisenberg, 1972; Bramblett et al., 1993). The lysate was then immediately centrifuged at 3,000 x g for 2 min at 25°C to remove the debris. An aliquot (100 μl) of the supernatant was sampled, dissolved in 400 μl of O+ buffer (62.5 mM Tris-HCl, pH 6.8; 10% glycerol; 5% 2-mercaptoethanol; 2.3% SDS; 1 mM EGTA; 1 mM EDTA; 1 mM PMSF; 1 mM Na3VO4; 1 mM NaF; 10 μl/ml of Protease Inhibitor Cocktail P8340, Sigma-Aldrich), a modified O buffer (O’Farrell, 1975), and boiled for 5 min. This is the total fraction, which includes both MT-free and bound fractions. Another aliquot (100 μl) of the supernatant was pelleted at 100,000 x g for 20 min at 25°C. The detergent-soluble supernatant was removed, and 80 μl were diluted in 320 μl of O+ buffer and boiled for 5 min. This was referred to as the MT-free fraction. The remaining pellet was resuspended in 100 μl of RA buffer, and diluted in 400 μl of O+ buffer and boiled for 5 min. This was referred to as the MT-bound fraction. Protein levels were quantified in all fractions.
We performed a similar assay with a buffer containing 30% glycerol as a MT stabilizer instead of taxol and GTP (Shelanski et al., 1973). This is an alternate technique also well documented (Esmaeli-Azad et al., 1994; Xie et al., 1998). Briefly, following dissection, fresh cortices were immediately homogenized in 5x weight/volume of pre-warmed (37°C) extraction buffer (80 mM MES, pH 6.8; 1 mM MgCl2; 2 mM EGTA; 30% glycerol; 0.1% Triton X-100; 1 mM PMSF; 1 mM Na3VO4; 1 mM NaF; 10 μl/ml Sigma Protease Inhibitor Cocktail P8340), in a warm (37°C) glass-teflon homogenizer. The lysate was then immediately centrifuged at 3,000 x g for 2 min at 25°C to remove the debris. An aliquot (100 μl) of the supernatant was sampled, dissolved in 400 μl of O+ buffer and boiled for 5 min. This is the total fraction, which includes both MT-free and bound fractions. Another aliquot (100 μl) of the supernatant was pelleted at 100,000 x g for 20 min at 25°C. The detergent-soluble supernatant was removed, and 80 μl were diluted in 320 μl of O+ buffer and boiled for 5 min. This was referred to as the MT free fraction. The remaining pellet was solubilized in 100 μl of RA buffer, and diluted in 400 μl of O+ buffer and boiled for 5 min. This was referred to as the MT-bound fraction.
Exogenous microtubule binding assay
The microtubule-binding assay was performed as described previously (Maas et al., 2000), with a few modifications. Hemispheres were homogenized in 5x weight/volume of BRB80 (Brinkley Reassembly Buffer; 80 mM PIPES/KOH pH 6.8, 1 mM EGTA, 1 mM MgCl2) with protease and phosphatase inhibitors. Homogenates were incubated on ice for 15 min and centrifuged at 20,000 x g for 20 min at 4°C. Supernatants were re-spun at 100,000 x g for 1 h at 4 °C. Equal amounts of protein lysate were used in each binding assay. High-speed supernatant fractions were adjusted to 1 mM GTP and 10 μM taxol and incubated with taxol-stabilized microtubules (30 μM, Cytoskeleton, Denver, CO) in a final volume of 50 μl for 10 min at 37 °C. The mixtures were centrifuged through 100 μl of 30% (w/v) sucrose cushions in BRB80 containing 1 mM GTP and 10 μM taxol, at 100,000 x g for 30 min at room temperature. The supernatant (MT free fraction) was collected and diluted with O+ buffer, and the pellet (MT bound fraction) was resuspended in O+ buffer.
Assembly assay
Following dissection, cortices were homogenized in 5x weight/volume of modified RA buffer. Homogenates were centrifuged for 5 min at 3000 x g at 4°C. Supernatants were boiled for 5 min and respun at 100,000 x g for 30 min at 4°C. Supernatants were used to check total tau expression levels by western blot using total tau antibody. The microtubule assembly assay was essentially carried out as described previously with a few modifications (Alonso et al., 2006). Heat stable lysates containing 300 ng of tau were mixed at 4°C with purified bovine brain MAP-free tubulin (5 mg/ml, Cytoskeleton, Denver, CO) and 1 mM GTP, all in polymerization buffer (100 mM MES, pH 6.7, 1 mM EGTA, 1 mM MgCl2) in a final volume of 80 μl. After rapid mixing, the samples were pipetted into quartz microcuvettes in a thermostatically controlled Hewlett Packard 8453 UV-Visible spectrophotometer. After 30 sec of equilibration at 37°C, the turbidity of the reaction mixture was continuously monitored at 350 nm for 10 min.
Antibodies
The following anti-tau monoclonal antibodies (specificity given in parentheses) were used: CP13, phospho-Ser202 (Weaver et al., 2000); TG-3, phospho-Ser231 and conformation specific; MC-6, phospho-Ser235 (Jicha et al., 1997); and PHF-1, phospho-Ser396/Ser404 (Otvos et al., 1994). Total tau was detected with either Tau T57120 (monoclonal, BD Transduction Laboratories, San Jose, CA), or Tau A0024 (polyclonal, Dako Cytomation, Carpinteria, CA). AT8 (Pierce Biotechnology, Rockford, IL) reacts with tau phosphorylated at Ser202/Thr205 (Goedert et al., 1995), and Tau-1 (Chemicon International, Temecula, CA) recognizes tau dephosphorylated at Ser195/Ser198/Ser199/Ser202 (Szendrei et al., 1993). Purified rabbit polyclonal anti-tau antibodies anti-tau phospho-Ser199, phospho-Ser262, and phospho-Ser422 were purchased from Biosource International, Camarillo, CA. Antibody 12E8, which recognizes phospho-Ser262/Ser356 (Seubert et al., 1995), was provided by Dr. Peter A. Seubert (Athena Neuroscience Inc., San Francisco, CA). RD3 and RD4, specific for 3-repeat (3RT) and 4-repeat (4RT) tau, were a gift from Dr. Rohan de Silva (University College, London, UK). Monoclonal antibodies Anti-α-Tubulin (B-5-1-2), Anti-β-Tubulin (TUB 2.1), Anti-Acetylated Tubulin (6-11B-1), and Anti-Tyrosine Tubulin (TUB-1A2) were purchased from Sigma-Aldrich. Polyclonal anti-Detyrosinated Tubulin (Glu-Tubulin, AB3201), was bought from Chemicon International.
Immunoblot analysis
Membrane blocking and antibody incubations were performed as described (Planel et al., 2001), with appropriate primary and secondary antibody dilutions. Anti-mouse and anti-rabbit HRP-conjugated secondary antibodies were purchased from Jackson ImmunoResearch, West Grove, PA. Immunoreactive bands were visualized and analyzed by enhanced chemiluminescence reagent (SuperSignal West Pico or Femto, Pierce Biotechnology) using a Fujifilm LAS3000 imaging system and the Image Gauge Mac OS X software. Serial dilutions of brain extract were assessed to obtain calibration curves for reliable quantification.
Immunohistochemistry
The brains of hTau mice, and tau knock-out mice were fixed by immersion in freshly prepared 4% paraformaldehyde (in PBS pH 7.4) overnight and cryoprotected in 30% sucrose solutions. Sagittal sections (40 μm) were cut through the brain using a cryostat (model HM 505 E; Microm International Gmbh, Walldorf, Germany). Immunohistochemistry was performed on free-floating brain sections using SuperPicTure™ polymer detection kit (Zymed, San Francisco, CA). Sections were washed with PBS for 10 min, and some were treated with 3 % H2O2 in PBS with 0.25% Triton X100 for 30 min at room temperature. For certain antibodies, epitope retrieval was also performed using sodium citrate buffer (10mM sodium citrate, 0.05% Tween 20, pH 6.0) according to a standard protocol (Shi et al., 1993). The sections were then blocked with 5% milk in PBS for 1h at room temperature on a rotator, transferred to a microfuge tube containing 1 ml of primary antibody diluted in 5% milk in PBS and incubated at 4°C overnight. After three washes of 5 min in PBS with 0.05% Triton X100, the sections were incubated for 2h with biotin-labeled secondary antibody in 20% Superblock (Pierce, #37535) in PBS with 0.05% Triton X100. After washing, the sections were incubated 1h with HRP polymer conjugate in 20% Superblock in PBS with 0.05% Triton X100. Following three washes, the staining was visualized using DAB chromogen. The stained sections were mounted on slides and coverslipped, and were examined using a Leica microscope.
Electron microscopy
Animals anesthetized briefly with isoflurane gas were perfused transcardially with 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.2, and optic nerve tract removed, post-fixed overnight in the same fixative. Samples were post-fixed with 1% osmium tetroxide, washed, dehydrated, and embedded in Epon-Araldite resin. The optic nerve was dissected and processed as described (Nixon et al., 1994). Thin sections of 1 μm thick for light microscopy were stained with toluidine blue to identify the area of the optic nerve, and 70 nm-thin sections for electron microscopy were stained with uranyl acetate and lead acetate before being examined with a transmission electron microscope (model CM 10; Philips). Images were captured on a CCD camera (model C4742-95; Hamamatsu Photonics, Hamamatsu, Bridgewater, NJ) and on Advantage CCD Camera System software (Advanced Microscopy Techniques Corporation, Danvers, MA). Ultrastructural analyses of optic nerve were performed at a level 2 mm from the retinal excavation.
Statistical analysis
Statistical analysis was performed with a two-tailed t-test, except were indicated. Data are means ± standard deviations (S.D.) or standard error of the mean (S.E.M.), as indicated in the figures; *, **, and *** symbols indicate significant differences with p < 0.05, p < 0.01, and p < 0.001, respectively.
In vivo tau hyperphosphorylation does not detach tau from microtubules in normal mice
We first performed the endogenous MT binding assay on young non-transgenic mice exposed to pentobarbital anesthesia for 1 h. Following anesthesia, the body temperature rapidly dropped from 38.3±0.3°C to 29.2±0.2°C. Although tau was significantly hyperphosphorylated, there was no change in the amount of tau bound to MTs compared to the tau in the MT-free fraction (data not shown). Thus hyperphosphorylation of tau for 1 h did not lead to its detachment from MTs in nontransgenic mice. We next examined whether longer exposure to hyperphosphorylation might be required to detach tau from MTs by analyzing the mice 4 h after the induction of anesthesia. After 4 h, the rectal temperature of the mice was 27.2±0.1°C. Tau was highly phosphorylated at all epitopes analyzed, in both the total and free fractions (Fig. 1 A & B, S202/T205 (AT8) and S396/S404 (PHF-1) epitopes displayed). As a result of hyperphosphorylation, tau underwent a mobility shift in the total and free fractions which was observed as a primary single band at 56 kD and a minor band at 50 kD in the control mice, compared to a primary doublet band at 60 kD, and 3 minor bands at 56, 64 and 70 kD after anesthesia (Fig. 1 C). The phosphorylation pattern of tau bound to MTs was also different, with no significant phosphorylation of S202/T205 (AT8), T231, S235, S262/S356 (12E8), and S422 epitopes (Fig. 1 A, S202/T205 epitope displayed), and significant hyperphosphorylation at S396/S404, S199, and S202 being observed in the anesthetized animals (Fig. 1 B, PHF-1 epitope displayed). The mobility shift of tau in the bound fraction was less pronounced than in the other fractions, with a primary band at 56 kD being observed in both control and anesthetized mice, and no clear bands at 64 and 70 kD. There was no significant change in either α-, β-, Tyr-, Glu- or Ac-tubulin in any of the fractions (Fig. 1 D, α-tubulin displayed). These results indicate that anesthesia-induced tau hyperphosphorylation for 4h does not detach tau from MTs, and does not destabilize MTs in normal mice. Interestingly, hyperphosphorylated tau detected in the total fraction mostly reflected tau from the free fraction. Tau bound to the MTs in the pelleted fraction appeared to be more resistant to hyperphosphorylation at some of the epitopes examined (S202/T205, T231, S235, S262/S356, and S422). This assay was performed using taxol to protect the MTs during the extraction process. While this technique is standard in the field and has been used by many (Bramblett et al., 1993; Merrick et al., 1996; Vogelsberg-Ragaglia et al., 2000), it should be noted that taxol is a powerful stabilizer of MT, and published data demonstrate that incubation at 37°C with taxol will displace all the soluble tubulin in the bound fraction (Xie et al., 1998). In our protocol, our samples are not incubated with taxol: we spin the homogenate immediately after extraction, and taxol is included only to prevent breakdown of MTs during the extraction process. Nevertheless, to verify that our results are not due to an artifact stemming from the presence of taxol, we performed the assay with a buffer containing 30% glycerol instead of taxol and GTP (Shelanski et al., 1973). This alternate technique is used by many groups (Esmaeli-Azad et al., 1994; Xie et al., 1998). The use of either taxol or glycerol demonstrated anesthesia-induced hyperphosphorylation of tau, with no detachment of tau from microtubules and no shift of tubulin in the free fraction (Fig. 1S). Finally, we performed the assay without taxol or glycerol and found similar results (data not shown).
Figure 1
Figure 1
Endogenous microtubule binding assay of tau after anesthesia in nontransgenic mice. Brain lysates (neocortex) from control mice and mice anesthetized for 4h with pentobarbital were prepared. Tau and tubulin from total, free and bound fractions were evaluated (more ...)
In vivo tau hyperphosphorylation prevents tau from binding and assembling microtubules
Our above data suggest that hyperphosphorylation does not detach tau from MTs in normal mice. To examine whether hyperphosphorylation alters the ability of tau to bind and stabilize MTs we compared the binding of tau from anesthetized and control mouse brain to exogenous, pre-formed MT. There was less tau in the MT bound fraction and more in the free fraction in anesthetized mice compared to controls (Fig. 2 A) for equivalent amounts of tubulin (Fig. 2 B). These results indicate that in vivo, hyperphosphorylation impaired tau’s capacity to bind pre-assembled MT. We next performed a MT assembly assay using purified bovine tubulin, and tau from control, or anesthetized mouse brains. Hyperphosphorylated tau from anesthetized mice was less efficient at promoting MT assembly than tau from control brains (Fig. 3). To perform this assay, we used tau from the heat-stable fraction which, however enriched in tau, contains other microtubule associated proteins that could be responsible for the differences in MT assembly rates between control and anesthetized mice. To exclude this possibility, we next performed the same assay with mice lacking tau (tau KO). Heat-stable fractions showed no difference between control and anesthetized tau KO mice (Fig. 2S), demonstrating that the effect of anesthesia on MT assembly are mediated through tau phosphorylation. Overall these results demonstrate that hyperphosphorylation impairs tau’s ability to bind, and promote MT assembly.
Figure 2
Figure 2
Exogenous microtubule binding assay of tau after anesthesia in non-transgenic mice. Brain proteins (neocortex) from control mice and mice anesthetized for 4h with pentobarbital were extracted and incubated with taxol-stabilized microtubules. Tau and tubulin (more ...)
Figure 3
Figure 3
Microtubule assembly assay of tau after anesthesia in non-transgenic mice. Brain homogenates (neocortex) from control mice and mice anesthetized for 4h with pentobarbital were prepared, and 300 ng of tau from the heat stable fractions was used to assemble (more ...)
In vivo tau hyperphosphorylation in hTau mice detaches tau from MT
In the AD brain, hyperphosphorylation has been proposed to lower the levels of MT bound tau below a critical threshold, thereby leading to destabilization of the MTs (Trojanowski and Lee, 1994). One possible reason why we did not observe this in our study is that mouse and human tau differ in the ratio of the isoforms, and mouse tau might be more difficult to detach from MT due to the fact that it is all 4R. To examine this possibility, we repeated our experiments in a line of mice that expresses all six isoforms of human tau in the absence of mouse tau (Duff et al., 2000; Andorfer et al., 2003).
We first performed the experiment in young hTau mice that do not yet have tau pathology. After 4 hours of anesthesia, the average body temperature fell to 28.9±2.6°C. As in non-TG mice, there was no detachment of tau from MTs or shift of tubulin to the unbound fraction (data not shown). One possible cause why hyperphosphorylation does not detach tau from the MT during anesthesia, while it would putatively detach in AD, would be that anesthesia-induced tau hyperphosphorylation levels are much lower than in AD. To exclude this possibility, we compared tau phosphorylation between anesthetized non-TG and hTau mice, and AD brains at Braak stage VI. There was no significant difference in phospho-tau levels (adjusted by total tau) between the 3 groups, indicating that, in theory, hyperphosphorylation levels reached during anesthesia should be enough to detach tau from MTs (Fig. 3S).
Another possibility why there is no change, is that the duration of tau phosphorylation during anesthesia (4 h) is not long enough to bring about detachment of tau and collapse of MTs. To address this possibility, we performed the same assay in mice starved for 3 days. Starvation induces hypothermia and extensive tau hyperphosphorylation (Planel et al., 2001; Planel et al., 2004). Interestingly, starvation led to greater phosphorylation of tau in the MT-bound fraction at certain epitopes such as AT8, but not at others such as pS262. However, there was still no detachment of tau from MTs or collapse of MTs (Fig. 4S).
To verify wether tau pathology influences the stability of the MT network, we then performed the same assay in old hTau mice that have mild pathology and somatodendritic relocalization of tau. In control mice, tau consisted of a doublet at 54 and 56 kD, with another band at 60 kD, and two minor bands at 51 and 67 kD (Fig. 4 C). After anesthesia, hyperphosphorylation was seen as a slight upward mobility shift of all the bands between 54 and 67 kD, with stronger bands at 56 and 60 kD in the total fraction. Tau was hyperphosphorylated at S202/T205 (AT8) and S396/S404 (PHF-1) sites in both total and free fractions, but was not significantly hyperphosphorylated in the bound fraction (Fig. 4 A & B). Other phosphorylation sites followed the same trend (data not shown). In addition, there was more tau in the free fraction and less tau in the bound fraction (Fig. 4C). No change in α-, β-, Tyr-, Glu- or Ac-tubulin was observed in any fraction (Fig. 4 D, α-tubulin shown). The same experiment performed in old non-TG mice did not lead to tau detachment from MTs (data not shown). Moreover, comparison of the levels of tau phosphorylation in control and anesthetized non-TG and hTau mice showed that, although tau phosphorylation is significantly higher in hTau control mice relative to total tau levels, the extent of hyperphosphorylation during anesthesia is similar in both mice (Fig. 5S). Taken together, these data suggest that detachment of tau from MTs during anesthesia in old hTau mice is not dependent on age or on the levels of tau phosphorylation, but on the extent of tau pathology. They also indicate that hyperphosphorylation can detach a fraction of human tau from MT without destabilizing them.
Figure 4
Figure 4
Endogenous microtubule binding assay of tau after anesthesia in hTau mice. Brain proteins (hippocampus and neocortex) from control mice and mice anesthetized for 4h with pentobarbital were extracted. Levels of tau and tubulin from total, free and bound (more ...)
Hyperphosphorylated 3R tau detaches from MTs in hTau mice
One of the main differences between mouse and humans with respect to tau is that adult humans continue to express 3R tau in addition to 4R tau, whereas adult mice only express 4R tau (Janke et al., 1999). To examine the isoform composition in the different fractions, immunoblots were prepared using antibodies specific to 3R or 4R tau (Andorfer et al., 2003; de Silva et al., 2003). There was more 3R tau in the free and less in the bound fraction after 4 h of anesthesia (Fig. 5 A). 4R tau levels did not change in either fraction (Fig. 5 B). This result was confirmed using ET1 (Andorfer et al., 2003), another 4R tau antibody (data not shown). Thus, in vivo, hyperphosphorylated 3R tau detaches from MTs more readily than 4R tau.
Figure 5
Figure 5
Endogenous microtubule binding assay of tau isoforms after anesthesia in hTau mice. Brain proteins (hippocampus and neocortex) from control mice and mice anesthetized for 4h with pentobarbital were extracted. Tau Total, Free and Bound fractions were evaluated (more ...)
Anesthesia leads to neuropil and somatic tau hyperphosphorylation in hTau mice
We previously reported the immunohistochemical analysis of anesthetized non-transgenic mice and demonstrated that hyperphosphorylated tau was localized in the neuropil and axonal tracks of anterior areas without somatodendritic relocalization (Planel et al., 2007b). Here, we examined the distribution of phospho-tau in control and anesthetized old hTau mice with antibodies recognizing tau phosphorylated at S202/T205 (AT8) and S396/S404 (PHF-1). AT8 showed weak staining in control mice (Fig. 6 A), but increased staining in the neuropil of anesthetized mice and some somatic staining (Fig. 6 B). PHF-1 staining was also observed in the neuropil of control mice, but it extended to the somatodendritic compartment after anesthesia (Fig. 6 C and D). These results confirm our immunoblot data which revealed a robust increase in phosphorylation at S202/T205 (Fig. 4 A) but less change in phosphorylation at the S396/S404 epitopes (Fig. 4 B). Our data suggest that tau in cell bodies is more readily phosphorylated at the S396/S404 epitopes. We next examined the gross anatomical distribution of tau in hTau mice. In unanesthetized, control hTau mice, total tau (Fig. 6 E, Tau, phospho-independent tau), and 3R tau (Fig. 6 H, 3RT) were present in the neuropil and in the soma of neurons. After anesthesia, there was no difference in staining with total tau (Fig. 6 F), but there was a visible increase of 3RT signal in the soma relative to control animals (compare Fig. 6 H and I). This could be due to an accumulation of 3R tau in the soma after anesthesia, or the result of conformational changes making the repeat region more accessible to the antibody. Staining with 4R tau specific antibody revealed the neuropil localization of 4R tau, but no difference in distribution was observed after anesthesia (Fig. 6 K and L). None of the antibodies immunolabeled the tau knock-out mouse brain tissue, confirming their specificity for tau (Fig. 6 G, J, M). Thus, anesthesia appeared to induce hyperphosphorylation of tau in the soma and the neuropil of hTau mice, that correlates with the specific detachment of 3R tau from MT observed previously (Fig. 5 A).
Figure 6
Figure 6
Tau immunostaining in the frontal cortex after anesthesia in hTau mice. Sagittal sections from control (A, C, E, H, K), anesthetized (B, D, F, I, L) hTau, or TKO (tau knock-out, used as negative staining control; G, J, M) mice were immunolabeled with (more ...)
Anesthesia does not induce MT reorganization in the optic nerve
To investigate the effect of hyperphosphorylation on the organization of the axonal cytoskeleton, we examined the ultrastructure of the optic nerve from control and anesthetized old hTau mice. Initial immunoblot studies confirmed that tau was hyperphosphorylated to a similar extent in this region as in the brain (data not shown). Inspection of electron micrographs from three mice in each group revealed no difference in the number of MTs or their spatial relationship to each other, and to neurofilaments, in axons of varying caliber (Fig. 7). These results demonstrate that detachment of 3R tau from the MTs did not induce MT reorganization in the axonal tracks of the optic nerve.
Figure 7
Figure 7
Ultrastructure of the cytoskeleton in axons of varying caliber from the optic nerve of control (A and C) and anesthetized (B and D) mice. There was no difference in numbers and the spatial relationships among microtubules, neurofilaments, and vesicular (more ...)
The induction tau hyperphosphorylation through anesthesia-induced hypothermia allowed us to investigate the effect of hyperphosphorylation on tau’s interaction with MTs in vivo. First, we have shown that under these conditions, MT-free tau was rapidly, and extensively hyperphosphorylated, impairing its capacity to bind MT and to promote MT assembly. Second, MT bound tau was more resistant to phosphorylation than free tau, and only 3R tau detached from MT in a transgenic line of mice expressing both 3R and 4R human tau with mild pathology. Third, even when 3R tau separated from MTs, there was no depolymerization of tubulin in the MT-bound fraction, and there was no collapse or disturbance of axonal MT networks.
Hyperphosphorylation of tau induced by kinase activity in cells and in vitro has repeatedly demonstrated that hyperphosphorylation impairs tau’s capacity to bind MT and to promote MT assembly. Inhibition of PP2A in cells also leads to tau hyperphosphorylation and renders it incompetent to associate with exogenous MTs (Shea and Fischer, 1996; Sontag et al., 1996). Thus, our data from wild-type mice confirm and extend these reports and represent the first demonstration that inhibition of PP2A by anesthesia-induced hypothermia in vivo (Planel et al., 2007b) results in hyperphosphorylation of MT-free tau which reduces its ability to bind and assemble MTs.
In contrast to free tau, MT-bound tau was resistant to phosphorylation at many epitopes, including S202/T205 (AT8), T231 (TG3), S235 (MC6), S262/S356 (12E8) and S422 which might be due to poor kinase accessibility of these residues when tau is associated with MTs. S262 in the MT-bound fraction proved to be especially resistant to phosphorylation, even after 3 days of hyperphosphorylation conditions. However, other sites on MT-bound tau such as sites recognized by S199, S202 (CP13), or S396/S404 (PHF-1) were hyperphosphorylated, which suggest that the conformation that tau takes on MTs leaves these epitopes accessible to phosphorylation events, and that they are less likely to regulate tau binding. Indeed, phosphorylation at sites such as T231, T231/S235, S262, or S262/S356 prevents tau from binding and stabilizing MTs (Biernat et al., 1993; Sengupta et al., 1998; Hamdane et al., 2003; Cho and Johnson, 2004), while phosphorylation at S202, S396, S396/S404, or S404 seems to have less impact on MT binding (Biernat et al., 1993; Cho and Johnson, 2003). When we applied the same experimental paradigm to hTau mice, we obtained similar results to non-transgenic mice: total and free tau (but not bound tau) was significantly phosphorylated at S202/T205, while total, free and bound tau were hyperphosphorylated at S396/S404. These results demonstrate that pools of MT-free and bound tau have a different sensitivity to hyperphosphorylating conditions.
When we examined the association of tau bound with endogenous MTs in response to hyperphosphorylating conditions during anesthesia, we found in wild-type mice that 4R tau did not separate from MTs independently of age. This is unlikely to be the result of a protective effect of hypothermia, as we showed previously that a low but sustained level of tau hyperphosphorylation in normothermic mice does not impair tau binding to MTs (Planel et al., 2007a). Also, the resistance to dissociation is probably a true failure to dissociate rather than a mere kinetic delay of dissociation, because we examined the mice 1 day and 1 week after anesthesia and did not see any significant change in total tau or tubulin in the different fractions (data not shown). In old hTau mice with mild pathology, there was an isoform specific dissociation of tau from MTs, as 3R, but not 4R tau, was detached. These results suggest that, in a pathological context, bound 3R tau is more sensitive than 4R to the effects of phosphorylation resulting in dissociation. 3R tau has been demonstrated to bind to MTs more weakly than 4R tau (Butner and Kirschner, 1991), and to be less efficient at promoting microtubule assembly (Goedert and Jakes, 1990; Gustke et al., 1994; Panda et al., 2003). In addition, published results suggest that 3R and 4R tau assume complex and distinct MT binding structures (Goode et al., 2000). Thus, the specific dissociation of 3R tau in old hTau mice might be due to a combination of higher baseline of phosphorylation due to pathology, weaker interactions with MTs, and greater accessibility to phosphorylation agents due to a different structural conformation on the surface of MTs.
Even when 3R tau dissociated from the MTs, depolymerization and collapse of the MT networks did not occur. One explanation might be that the remaining tau bound to MTs was sufficient enough to stabilize the cytoskeletal structure. Indeed, tau has been found to fulfill its stabilizing function in very minute amounts (Levy et al., 2005). Another possibility comes from the suggestion that 3R and 4R tau might have distinct functions on MTs that are regulated differentially (Goode et al., 2000); thus, if 4R tau were the primary stabilizer of MTs in vivo, detachment of 3R only would have no impact on MT networks. These results are in marked contrast with others reported in the literature: all the data from cell culture studies demonstrate that tau hyperphosphorylation mediated by kinase overactivation or phosphatase inhibition results in tau dissociation from MTs and destruction of MT networks (Gurland and Gundersen, 1993; Sontag et al., 1996; Merrick et al., 1997; Kim et al., 1999). This discrepancy might be due to the difference in the speed of the assembly process between cellular models and living animals. MT function requires dynamic equilibrium between the formation of polymerized and depolymerized MTs (Desai and Mitchison, 1997). For example, in fibroblasts, turnover can be very fast: tubulin protomers have a half-life of 1 day, but the MTs formed from them are very dynamic (t1/2~5min; Schulze, 1987). In vitro studies on cultured neurons show that growing axons contain a high percentage of stable MT polymers with a half-life of more than 2h (Li and Black, 1996). In vivo, MTs in mature axons are likely to be even more stable, and studies suggest that some MTs can last for months (Garner, 1988; Tanner et al., 1995). Thus, longer exposure to hyperphosphorylating conditions in vivo (months or years instead of hours or days) might result in less 4R tau bound to MTs and might lead to partial MT collapse. However, this would be more likely due to MT turnover and the failure of MTs to recruit hyperphosphorylated free tau rather than dissociation of 4R tau already bound to MTs.
Our results might have clinical relevance, as anesthesia appears to be associated with long-term cognitive dysfunction and the acceleration of senile dementia (Ritchie et al., 1997; Xie and Tanzi, 2006). Several reports have suggested that anesthesia could increase the risk of AD (Bohnen et al., 1994; Johansson and Skoog, 1996; Bone and Rosen, 2000), and hypothermia has also been proposed as a risk factor (Holtzman and Simon, 2000; Avila and Diaz-Nido, 2004). The combination of regional or general anesthetic exposure and cool operating room environment make most surgical patients hypothermic (Sessler, 2000). While hypothermia may be beneficial for specific, critically ill patients, perioperative hypothermia following anesthesia is clearly harmful for most patients (Sessler, 1997, 2001). It is therefore encouraging for surgery patients that tau hyperphosphorylation after 4h of anesthesia did not lead to a collapse of MTs. However, the fact that this detachment occurs only when the mice are older and have mild pathology underscores the vulnerability of the elderly, particularly if they have incipient AD. Interestingly, studies on tau splicing in embryos suggest that 3R tau could permit a higher degree of neuronal plasticity, as it is the main isoform expressed during early development (Kosik et al., 1989; Avila et al., 1994; Janke et al., 1999; Takuma et al., 2003). In addition, tau isoforms seem to have opposite effects on MT, with 4R tau promoting and 3R tau reducing MT growth rate, which may be utilized by the cells to finely regulate MT dynamics (Levy et al., 2005). Thus, specific detachment of 3R tau following anesthesia might have the counter-intuitive effect of decreasing MT dynamics and neuronal plasticity. Whether 3R tau detachment could have any role in the postoperative cognitive dysfunction that is common after general anesthesia remains an open question (Ancelin et al., 2001). Lastly, it should be noted that our study was done with pentobarbital, an intravenous anesthetics not known to interact with MTs. In contrast, volatile anesthetics have been shown to interact directly with tubulin, alter MTs quaternary structure, affect tubulin expression, and reduce MT density in neurons (reviewed in (Eckenhoff and Eckenhoff, 2007). Future studies should therefore examine the effect of volatile anesthetics on tau phosphorylation and MT stability, with and without hypothermia.
Overall, our data imply that MTs do not easily disassemble in mammals, and provide limiting parameters to any putative disassembly of MTs resulting from tau hyperphosphorylation rather than disprove that it would occur. In vivo hyperphosphorylation of tau seems more likely to affect MT networks in the long term, by preventing free tau from binding and stabilizing MTs, rather than by overtly dissociating tau already bound to them.
Supplementary Material
Supp1
Supp2
Supp3
Supp4
Supp5
Acknowledgements
We thank Dr. Aidong Yuan and Corrine M. Peterhoff (NKI, CDR, Orangeburg, NY) for technical assistance. We are grateful to Drs. Rohan de Silva (University College, London, UK), and Peter A. Seubert (Athena Neuroscience Inc., San Francisco, CA), for the generous gift of antibodies. This work was supported by National Institute of Neurological Disorders and Stroke Grant NS048447 and National Institute of Aging AG017216 (to K.E.D.).
  • Alonso AC, Li B, Grundke-Iqbal I, Iqbal K. Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A. 2006;103:8864–8869. [PubMed]
  • Alonso AC, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments / straight filaments. Proc Natl Acad Sci U S A. 2001;98:6923–6928. [PubMed]
  • Ancelin ML, de Roquefeuil G, Ledesert B, Bonnel F, Cheminal JC, Ritchie K. Exposure to anaesthetic agents, cognitive functioning and depressive symptomatology in the elderly. Br J Psychiatry. 2001;178:360–366. [PubMed]
  • Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582–590. [PubMed]
  • Avila J, Diaz-Nido J. Tangling with hypothermia. Nat Med. 2004;10:460–461. [PubMed]
  • Avila J, Dominguez J, Diaz-Nido J. Regulation of microtubule dynamics by microtubule-associated protein expression and phosphorylation during neuronal development. Int J Dev Biol. 1994;38:13–25. [PubMed]
  • Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84:361–384. [PubMed]
  • Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron. 1993;11:153–163. [PubMed]
  • Bohnen N, Warner MA, Kokmen E, Kurland LT. Early and midlife exposure to anesthesia and age of onset of Alzheimer’s disease. Int J Neurosci. 1994;77:181–185. [PubMed]
  • Bone I, Rosen M. Alzheimer’s disease and anaesthesia. Anaesthesia. 2000;55:592–593. [PubMed]
  • Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron. 1993;10:1089–1099. [PubMed]
  • Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:95–130. [PubMed]
  • Butner KA, Kirschner MW. Tau protein binds to microtubules through a flexible array of distributed weak sites. J Cell Biol. 1991;115:717–730. [PMC free article] [PubMed]
  • Cho JH, Johnson GV. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem. 2003;278:187–193. [PubMed]
  • Cho JH, Johnson GV. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau’s ability to bind and stabilize microtubules. J Neurochem. 2004;88:349–358. [PubMed]
  • de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, Bandopadhyay R, Utton M, Strand C, Jowett T, Khan N, Anderton B, Wood N, Holton J, Revesz T, Lees A. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol. 2003;29:288–302. [PubMed]
  • Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol. 1997;13:83–117. [PubMed]
  • Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M, Adamson J, Goedert M, Burki K, Davies P. Characterization of Pathology in Transgenic Mice Over-Expressing Human Genomic and cDNA Tau Transgenes. Neurobiol Dis. 2000;7:87–98. [PubMed]
  • Ebneth A, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of MAP2c and MAP4 by MARK kinases leads to the destabilization of microtubules in cells. Cell Motil Cytoskeleton. 1999;44:209–224. [PubMed]
  • Eckenhoff RG, Eckenhoff MF. Anesthesia, Amyloid and Alzheimer’s. Cellscience Reviews. 2007;4:78–96.
  • Esmaeli-Azad B, McCarty JH, Feinstein SC. Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J Cell Sci. 1994;107(Pt 4):869–879. [PubMed]
  • Feinstein SC, Wilson L. Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim Biophys Acta. 2005;1739:268–279. [PubMed]
  • Garner JA. Differential turnover of tubulin and neurofilament proteins in central nervous system neuron terminals. Brain Res. 1988;458:309–318. [PubMed]
  • Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. Embo J. 1990;9:4225–4230. [PubMed]
  • Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189:167–169. [PubMed]
  • Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem. 1993;61:921–927. [PubMed]
  • Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem. 1995;65:732–738. [PubMed]
  • Goode BL, Chau M, Denis PE, Feinstein SC. Structural and functional differences between 3-repeat and 4-repeat Tau isoforms: Implications for normal Tau function and the onset of neurodegenerative disease. J Biol Chem. 2000 [PubMed]
  • Gurland G, Gundersen GG. Protein phosphatase inhibitors induce the selective breakdown of stable microtubules in fibroblasts and epithelial cells. Proc Natl Acad Sci U S A. 1993;90:8827–8831. [PubMed]
  • Gustke N, Trinczek B, Biernat J, Mandelkow EM, Mandelkow E. Domains of tau protein and interactions with microtubules. Biochemistry. 1994;33:9511–9522. [PubMed]
  • Hamdane M, Sambo AV, Delobel P, Begard S, Violleau A, Delacourte A, Bertrand P, Benavides J, Buee L. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J Biol Chem. 2003;278:34026–34034. [PubMed]
  • Holtzman A, Simon EW. Body temperature as a risk factor for Alzheimer’s disease. Med Hypotheses. 2000;55:440–444. [PubMed]
  • Janke C, Beck M, Stahl T, Holzer M, Brauer K, Bigl V, Arendt T. Phylogenetic diversity of the expression of the microtubule-associated protein tau: implications for neurodegenerative disorders. Brain Res Mol Brain Res. 1999;68:119–128. [PubMed]
  • Jicha GA, Lane E, Vincent I, Otvos L, Jr., Hoffmann R, Davies P. A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer’s disease. J Neurochem. 1997;69:2087–2095. [PubMed]
  • Johansson C, Skoog I. A population-based study on the association between dementia and hip fractures in 85-year olds. Aging (Milano) 1996;8:189–196. [PubMed]
  • Kim D, Su J, Cotman CW. Sequence of neurodegeneration and accumulation of phosphorylated tau in cultured neurons after okadaic acid treatment. Brain Res. 1999;839:253–262. [PubMed]
  • Kosik KS, Orecchio LD, Bakalis S, Neve RL. Developmentally regulated expression of specific tau sequences. Neuron. 1989;2:1389–1397. [PubMed]
  • Levy SF, Leboeuf AC, Massie MR, Jordan MA, Wilson L, Feinstein SC. Three-and four-repeat tau regulate the dynamic instability of two distinct microtubule subpopulations in qualitatively different manners. Implications for neurodegeneration. J Biol Chem. 2005;280:13520–13528. [PubMed]
  • Li Y, Black MM. Microtubule assembly and turnover in growing axons. J Neurosci. 1996;16:531–544. [PubMed]
  • Maas T, Eidenmuller J, Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem. 2000;275:15733–15740. [PubMed]
  • Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging. 2003;24:1079–1085. [PubMed]
  • Merrick SE, Demoise DC, Lee VM. Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A. J Biol Chem. 1996;271:5589–5594. [PubMed]
  • Merrick SE, Trojanowski JQ, Lee VM. Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons. J Neurosci. 1997;17:5726–5737. [PubMed]
  • Mi K, Johnson GV. The role of tau phosphorylation in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res. 2006;3:449–463. [PubMed]
  • Nixon RA, Paskevich PA, Sihag RK, Thayer CY. Phosphorylation on carboxyl terminus domains of neurofilament proteins in retinal ganglion cell neurons in vivo: influences on regional neurofilament accumulation, interneurofilament spacing, and axon caliber. J Cell Biol. 1994;126:1031–1046. [PMC free article] [PubMed]
  • O’Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem. 1975;250:4007–4021. [PMC free article] [PubMed]
  • Otvos L, Jr., Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 1994;39:669–673. [PubMed]
  • Panda D, Samuel JC, Massie M, Feinstein SC, Wilson L. Differential regulation of microtubule dynamics by three- and four-repeat tau: Implications for the onset of neurodegenerative disease. Proc Natl Acad Sci U S A. 2003;100:9548–9553. [PubMed]
  • Planel E, Yasutake K, Fujita SC, Ishiguro K. Inhibition of protein phosphatase 2A overrides Tau protein kinase I / glycogen synthase kinase 3beta and Cyclindependant kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem. 2001;276:34298–34306. [PubMed]
  • Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer’s disease. J Neurosci. 2004;24:2401–2411. [PubMed]
  • Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, Herman M, Yu WH, Luchsinger JA, Wadzinski B, Duff KE, Takashima A. Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci. 2007a;27:13635–13648. [PubMed]
  • Planel E, Richter KEG, Nolan CE, Finley JE, Liu L, Wen Y, Krishnamurthy P, Herman M, Wang L, Schachter JB, Nelson RB, Lau L-F, Duff KE. Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci. 2007b;27:3090–3097. [PubMed]
  • Pollak D, Cairns N, Lubec G. Cytoskeleton derangement in brain of patients with Down syndrome, Alzheimer’s disease and Pick’s disease. J Neural Transm. 2003;(Suppl):149–158. [PubMed]
  • Ritchie K, Polge C, deRoquefeuil G, Djakovic M, Ledesert B. Impact of anesthesia on the cognitive functioning of the elderly. Int Psychogeriatr. 1997;9:309–326. [PubMed]
  • Sato S, Tatebayashi Y, Akagi T, Chui DH, Murayama M, Miyasaka T, Planel E, Tanemura K, Sun X, Hashikawa T, Yoshioka K, Ishiguro K, Takashima A. Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J Biol Chem. 2002;277:42060–42065. [PubMed]
  • Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys. 1998;357:299–309. [PubMed]
  • Sessler DI. Mild perioperative hypothermia. N Engl J Med. 1997;336:1730–1737. [PubMed]
  • Sessler DI. Perioperative heat balance. Anesthesiology. 2000;92:578–596. [PubMed]
  • Sessler DI. Complications and treatment of mild hypothermia. Anesthesiology. 2001;95:531–543. [PubMed]
  • Seubert P, Mawal-Dewan M, Barbour R, Jakes R, Goedert M, Johnson GV, Litersky JM, Schenk D, Lieberburg I, Trojanowski JQ, et al. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem. 1995;270:18917–18922. [PubMed]
  • Shea TB, Fischer I. Phosphatase inhibition in human neuroblastoma cells alters tau antigenicity and renders it incompetent to associate with exogenous microtubules. FEBS Lett. 1996;380:63–67. [PubMed]
  • Shelanski ML, Gaskin F, Cantor CR. Microtubule assembly in the absence of added nucleotides. Proc Natl Acad Sci U S A. 1973;70:765–768. [PubMed]
  • Shi SR, Chaiwun B, Young L, Cote RJ, Taylor CR. Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections. J Histochem Cytochem. 1993;41:1599–1604. [PubMed]
  • Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron. 1996;17:1201–1207. [PubMed]
  • Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, White CL., 3rd Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol. 2004;63:287–301. [PubMed]
  • Szendrei GI, Lee VM, Otvos L., Jr. Recognition of the minimal epitope of monoclonal antibody Tau-1 depends upon the presence of a phosphate group but not its location. J Neurosci Res. 1993;34:243–249. [PubMed]
  • Takuma H, Arawaka S, Mori H. Isoforms changes of tau protein during development in various species. Brain Res Dev Brain Res. 2003;142:121–127. [PubMed]
  • Tanimukai H, Grundke-Iqbal I, Iqbal K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer’s disease. Am J Pathol. 2005;166:1761–1771. [PubMed]
  • Tanner SL, Storm EE, Bittner GD. Maintenance and degradation of proteins in intact and severed axons: implications for the mechanisms of long-term survival of anucleate crayfish axons. J Neurosci. 1995;15:540–548. [PubMed]
  • Terry RD. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol. 1996;55:1023–1025. [PubMed]
  • Tian Q, Wang J. Role of serine/threonine protein phosphatase in Alzheimer’s disease. Neurosignals. 2002;11:262–269. [PubMed]
  • Trojanowski JQ, Lee VM. Paired helical filament tau in Alzheimer’s disease. The kinase connection. Am J Pathol. 1994;144:449–453. [PubMed]
  • Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease hippocampus. Exp Neurol. 2001;168:402–412. [PubMed]
  • Vogelsberg-Ragaglia V, Bruce J, Richter-Landsberg C, Zhang B, Hong M, Trojanowski JQ, Lee VM. Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. Mol Biol Cell. 2000;11:4093–4104. [PMC free article] [PubMed]
  • Weaver CL, Espinoza M, Kress Y, Davies P. Conformational change as one of the earliest alterations of tau in Alzheimer’s disease. Neurobiol Aging. 2000;21:719–727. [PubMed]
  • Weisenberg RC. Microtubule formation in vitro in solutions containing low calcium concentrations. Science. 1972;177:1104–1105. [PubMed]
  • Xie H, Litersky JM, Hartigan JA, Jope RS, Johnson GV. The interrelationship between selective tau phosphorylation and microtubule association. Brain Res. 1998;798:173–183. [PubMed]
  • Xie Z, Tanzi RE. Alzheimer’s disease and post-operative cognitive dysfunction. Exp Gerontol. 2006;41:346–359. [PubMed]